替尔泊肽的免疫原性对药代动力学、疗效和安全性的影响:来自3期研究数据的分析
分析7项3期试验中5025例接受替尔泊肽治疗2型糖尿病患者的治疗中出现抗药抗体(TE ADA),51.1%出现TE ADA且各组比例相似,TE ADA状态、滴度和中和抗体状态不影响药代动力学或疗效,TE ADA阳性者超敏和注射部位反应更多但多为非严重非重度。
要点
- 替尔泊肽治疗患者中51.1%出现治疗中出现抗药抗体(TE ADA),各剂量组比例相似。
- TE ADA状态、滴度及中和抗体状态对替尔泊肽药代动力学和疗效无影响。
- TE ADA阳性患者超敏反应或注射部位反应更多,但多数为非严重、非重度。
核心结论
- 免疫原性未影响替尔泊肽的药代动力学或疗效,TE ADA阳性患者的大多数超敏或注射部位反应为轻至中度严重程度。
研究设计与样本
- 基于7项3期试验(SURPASS-1、-2、-3、-4、-5、Japan-Mono和Japan-Combo)的分析,纳入可评估ADA的接受替尔泊肽治疗2型糖尿病患者N=5025。
- ADA在基线和研究全程至终点(第40周或第52周)评估,替尔泊肽剂量为5、10或15 mg。
主要发现
- 51.1%的替尔泊肽治疗患者出现TE ADA,各剂量组比例相似。
- TE ADA阳性患者中最大ADA滴度范围为1:20至1:81920。
- 针对替尔泊肽在GIP和GLP-1受体活性的中和抗体(NAb)分别见于1.9%和2.1%的患者。
- 不到1.0%的患者有针对天然GIP(nGIP)或天然GLP-1(nGLP-1)的交叉反应性NAb。
- TE ADA状态、ADA滴度和NAb状态对替尔泊肽的药代动力学或疗效无影响;TE ADA阳性患者比TE ADA阴性患者经历更多超敏反应或注射部位反应,但大多数超敏和注射部位反应为非严重且非重度。
关键数值与推荐
- TE ADA发生率51.1%;NAb针对替尔泊肽GIP受体活性1.9%、GLP-1受体活性2.1%;交叉反应性NAb针对nGIP或nGLP-1<1.0%。
- 最大ADA滴度范围1:20至1:81920。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Antidrug antibodies (ADA) can potentially affect drug pharmacokinetics, safety, and efficacy. OBJECTIVE: This work aimed to evaluate treatment-emergent (TE) ADA in tirzepatide (TZP)-treated participants across 7 phase 3 trials and their potential effect on pharmacokinetics, efficacy, and safety. METHODS: ADA were assessed at baseline and throughout the study until end point, defined as week 40 (SURPASS-1, -2, and -5) or week 52 (SURPASS-3, -4, Japan-Mono, and Japan-Combo). Samples for ADA characterization were collected at SURPASS trial sites. Participants included ADA-evaluable TZP-treated patients with type 2 diabetes (N = 5025). Interventions included TZP 5, 10, or 15 mg. ADA were detected and characterized for their ability to cross-react with native glucose-dependent insulinotropic polypeptide (nGIP) and glucagon-like peptide-1 (nGLP-1), neutralize tirzepatide activity on GIP and GLP-1 receptors, and neutralize nGIP and nGLP-1. RESULTS: TE ADA developed in 51.1% of tirzepatide-treated patients. Proportions were similar across dose groups. Maximum ADA titers ranged from 1:20 to 1: 81 920 among TE ADA+ patients. Neutralizing antibodies (NAb) against TZP activity on GIP and GLP-1 receptors were observed in 1.9% and 2.1% of patients, respectively. Less than 1.0% of patients had cross-reactive NAb against nGIP or nGLP-1. TE ADA status, ADA titer, and NAb status had no effect on the pharmacokinetics or efficacy of TZP. More TE ADA+ patients experienced hypersensitivity reactions or injection site reactions than TE ADA- patients. The majority of hypersensitivity and injection site reactions were nonserious and nonsevere, and most events occurred and/or resolved irrespective of TE ADA status or titer. CONCLUSION: Immunogenicity did not affect TZP pharmacokinetics or efficacy. The majority of hypersensitivity or injection site reactions experienced by TE ADA+ patients were mild to moderate in severity.
引用
- Mullins GR, Hodsdon ME, Li YG, et al. Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. J Clin Endocrinol Metab. 2024. PMID: 37700637. doi:10.1210/clinem/dgad532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。